The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
Morning Overview on MSN
Researchers think they’ve found a path to restoring human vision
For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...
Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy ...
Please provide your email address to receive an email when new articles are posted on . Patients with multiple sclerosis were found to have alterations in binocular vision, particularly if optic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback